Clometro 7HP

Clometro 7HP Drug Interactions





SM Pharmaceuticals


SM Pharmaceuticals
Full Prescribing Info
Drug Interactions
Claritrox 250 mg Tablet: Carbamazepine: administration of carbamazepine with clarithromycin has been shown to increase significantly the plasma concentration of carbamazepine; carbamazepine serum levels should be monitored.
Digoxin: concurrent administration of digoxin with clarithromycin has been shown to increase serum digoxin concentrations; monitoring of digoxin serum levels is recommended.
Rifabutin or Rifampin: concurrent use of clarithromycin and rifabutin or rifampin decreases the serum concentration of clarithromycin by >50%.
Terfenadine: concurrent use of clarithromycin and terfenadine may increase the plasma concentration of terfenadine and its active metabolite by 2 to 3 times; concurrent use should be avoided.
Theophylline: concurrent administration with clarithromycin has been shown to increase the AUC of theophylline by 17 %; monitoring of theophylline serum levels is recommended.
Warfarin: concurrent administration with clarithromycin has been shown to potentiate the effects of warfarin; prothrombin time should be closely monitored.
Ergotamine or dihydroergotamine: concurrent use with clarithromycin has been associated in some patients with acute ergot toxicity.
Triazolam: There have been reports of CNS effects with the concomitant use of clarithromycin and triazolam.
Cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, Quinidine/disopyramide, lovastatin, bromocriptine, valproate, astemizole and other drugs metabolised by the cytochrome P450 system: concurrent use with clarithromycin may be associated with elevations in serum levels of these other drugs; serum concentrations should be closely monitored.
Drug metabolised by CYP3A isoenzyme: Clarithromycin has the potential to interact with the large number of drugs through its action on hepatic cytochrome P450 isoenzymes. Such interactions can result in severe adverse effects, including ventricular arrhythmias with the non-sedative antihistamines astemizole and terfenadine and with the prokinetic drug cisapride.
Zidovudine: Simultaneous oral administration of zidovudine and clarithromycin resulted in a lower peak serum concentration [Cmax], lower AUC, and delayed time to peak concentration [Tmax] of zidovudine should be taken at least hours apart.
Metgyl 400 mg Tablet: Alcohol: It is recommended that the metronidazole not be used concurrently with ingestion of alcohol may resulting in disulfiram-like effects.
Anticoagulants, coumarin- or indandione-derivative: Effects may be potentiated when these agents are used concurrently with metronidazole, periodic prothrombin time determinations may be required to determine if dosage adjustments anticoagulants are necessary.
Cimetidine: Hepatic metabolism of metronidazole may be decreased when metronidazole and cimetidine are used concurrently, possibly resulting in delayed elimination and increased serum metronidazole concentrations.
Disulfiram: It is recommended that metronidazole not be used concurrently with, or for 2 weeks following, disulfiram in alcoholic patients; such use may result in confusion and psychotic reactions.
Lithium: Lithium concentrations may increase when metronidazole therapy is introduced; serum lithium and serum creatinine levels should be monitored several days after beginning metronidazole in order to detect impending lithium intoxication.
Phenobarbital: Phenobarbital may induce microsomal liver enzymes, increasing metronidazole's metabolism and resulting in a decrease in half-life and plasma concentration.
Phenytoin: Metronidazole may impair the clearance of phenytoin, increasing phenytoin's plasma concentration.
Aspartate amino transferase assay: It may give spuriously low values in patients taking metronidazole depending on the method used.
Omilock 20 mg Capsule: Digoxin: Simultaneous treatment with omeprazole and digoxin in healthy subjects lead to a 10% increase in the bioavailability of digoxin as a consequence of the increased intragastric pH.
Diazepam, Phenytoin and Warfarin: Omeprazole inhibits the metabolism of drugs metabolised by the hepatic cytochrome P450 enzyme system and may increase plasma concentrations of diazepam, phenytoin, and warfarin. Interaction with other drugs also metabolised via cytochrome P-450 system cannot be excluded.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in